99% Apixaban CAS 503612-47-3

Lus piav qhia luv luv:

Lub npe tshuaj:Apixaban
Lwm lub npe:1-(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine -3-carboxaMide;1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,
5-dihydropyrazolo [3,4-c]pyridine-3-carboxaMide
CAS Nr:.503612-47-3
Purity:99% min
Formula:C25H25N5O4
Molecular Luj:459.50 Nws
Chemical Properties:Apixaban yog dawb crystalline hmoov.Nws yog ib daim ntawv tshiab ntawm qhov ncauj Xa factor inhibitor, thiab nws lub npe lag luam yog Eliquis.Apixaban yog siv los kho cov neeg laus cov neeg laus uas tau xaiv lub duav lossis lub hauv caug hloov phais kom tiv thaiv venous thromboembolism (VTE).

Xa email rau peb

Product Detail

Khoom cim npe

Specification

Yam khoom	STANDARD
Qhov tshwm sim	Dawb mus rau dawb dawb
Purity	≥ 99%

Daim ntawv thov

Apixaban yog ib yam tshiab ntawm qhov ncauj anticoagulant, ib yam tshiab ntawm qhov ncauj qhov tseem ceeb Xa inhibitor, uas yog siv los tiv thaiv thiab kho cov ntshav txhaws.
Apixaban yog lub qhov ncauj tshiab Xa inhibitor sib koom ua ke tsim los ntawm Bristol-Myers Squibb thiab Pfizer.Los ntawm inhibiting ib qho tseem ceeb coagulation yam Xa, apixaban tiv thaiv thrombin tiam thiab thrombosis.

Thaum Lub Plaub Hlis 26, 2007, Bristol-Myers Squibb thiab Pfizer tshaj tawm kev sib koom ua ke ntawm qhov ncauj tshuaj tiv thaiv kab mob tshiab apixaban uas yog Bristol-Myers Squibb ua ib qho kev hloov kho rau warfarin.
Nyob rau lub Tsib Hlis 2011, apixaban yog thawj zaug tau txais kev pom zoo rau kev tiv thaiv ntawm venous thrombosis nyob rau hauv cov neeg laus cov neeg laus uas tau xaiv lub duav los yog lub hauv caug hloov pauv nyob rau hauv 27 EU lub teb chaws, Iceland thiab Norway.
Thaum Lub Kaum Ib Hlis 20, 2012, European Commission tau pom zoo ELIQUIS (apixaban) rau kev tiv thaiv mob hlab ntsha tawg thiab cov kab mob embolism hauv cov neeg laus uas tsis yog-valvular atrial fibrillation (NVAF) nrog ib lossis ntau qhov kev pheej hmoo.
Lub Canadian Food and Drug Administration, Nyiv, thiab US Food and Drug Administration tom qab pom zoo ELIQUIS (apixaban) rau kev tiv thaiv mob stroke thiab systemic embolism nyob rau hauv cov neeg laus uas tsis yog-valvular atrial fibrillation (NVAF) nrog ib tug los yog ntau yam muaj feem yuav.
Lub Plaub Hlis 12, 2013, ELIQUIS (Apixaban), tau tshaj tawm hauv kev lag luam hauv Suav teb.Apixaban yog ib qho tshiab qhov ncauj qhov ncauj Xa inhibitor rau kev tiv thaiv ntawm venous thromboembolism (VTE) nyob rau hauv cov neeg laus cov neeg mob uas tau xaiv lub duav los yog lub hauv caug hloov phais.Nws qhov kev tshaj tawm muab kev nyab xeeb thiab muaj txiaj ntsig kev xaiv tshiab rau kev tiv thaiv kab mob tom qab phais orthopedic hauv kev kho mob, thiab coj xov xwm zoo rau cov neeg mob Suav uas tau xaiv lub duav / lub hauv caug hloov.
Cov kev tshawb fawb soj ntsuam tau lees paub tias piv nrog 40 mg subcutaneous txhaj ntawm enoxaparin ib hnub ib zaug, 2.5 mg ntawm ELIQUIS (Apixaban) qhov ncauj ob zaug hauv ib hnub yog qhov ua tau zoo dua los tiv thaiv venous thromboembolic cov xwm txheej tom qab lub duav lossis lub hauv caug hloov, thiab tsis ua rau muaj kev pheej hmoo ntawm los ntshav.